title: Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial.
abstract: OBJECTIVE
  To assess the impact on survival of high-dose chemotherapy with haematopoietic support in patients with high-volume, metastatic nonseminomatous germ cell tumours.
  
  
  METHODS
  One hundred fifteen patients were randomised to receive either four cycles every 21 d of vinblastine (0.2 mg/kg on day 1), etoposide (100 mg/m2/d on days 1 through 5), cisplatin (40 mg/m2/d on days 1 through 5), and bleomycin (30 mg on days 1, 8, and 15) (arm A), or a slightly modified regimen followed by a high-dose chemotherapy including etoposide (350 mg/m2/d on days 1 through 5), cisplatin (40 mg/m2/d on days 1 through 5), and cyclophosphamide (1600 mg/m2/d on days 2 through 5) (arm B).
  
  
  RESULTS
  In an intent-to-treat analysis, there were 32 (56%) and 24 (42%) complete responses in arms A and B, respectively (p=0.099). After a median follow-up of 9.7 yr, 31 and 27 patients have continuously shown no evidence of disease in arms A and B, respectively. There was no significant difference between the overall survival curves (p=0.167). According to the International Germ Cell Cancer Collaborative Group prognostic classification, the 5-yr survival rates were 88% and 82% in the intermediate group and 69% and 44% in the poor group (p=0.045) in arms A and B, respectively.
  
  
  CONCLUSIONS
  This trial failed to demonstrate an impact on response and survival of high-dose chemotherapy with haematopoietic support in first-line treatment of patients with high-volume, metastatic nonseminomatous germ cell tumours.
authors.affiliation: Centre Léon Bérard, Lyon, France.
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Droz
authors.forename: Andrew
authors.initials: A
authors.lastname: Kramar
authors.forename: Pierre
authors.initials: P
authors.lastname: Biron
authors.forename: José-Luis
authors.initials: JL
authors.lastname: Pico
authors.forename: Pierre
authors.initials: P
authors.lastname: Kerbrat
authors.forename: Jean
authors.initials: J
authors.lastname: Pény
authors.forename: Hervé
authors.initials: H
authors.lastname: Curé
authors.forename: Christine
authors.initials: C
authors.lastname: Chevreau
authors.forename: Christine
authors.initials: C
authors.lastname: Théodore
authors.forename: Jeannine
authors.initials: J
authors.lastname: Bouzy
authors.forename: Stéphane
authors.initials: S
authors.lastname: Culine
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000556:secondary* / Q000628:therapy*; D013736:Testicular Neoplasms / Q000473:pathology* / Q000628:therapy*; D017211:Treatment Failure
chemical_list: D000970:Antineoplastic Agents; D005047:Etoposide; D003520:Cyclophosphamide; D002945:Cisplatin